title: [Expression of P53 and PCNA in nasopharyngeal carcinoma and their relation with clinical stage, VCA/IgA, EA/IgA, radiation sensibility, and pognosis].
abstract: OBJECTIVE
  P53 and proliferating cell nuclear antigen(PCNA) relate with tumorigenesis, development, and prognosis of malignant tumors. This study was to detect expression of P53 and PCNA in nasopharyngeal carcinoma (NPC) tissue, and discuss their relation of p53 and PCNA expression with clinical stage, VCA/IgA, EA/IgA, radiation sensibility, and prognosis.
  
  
  METHODS
  Immunohistochemistry was used to detect P53 and PCNA expression in NPC tissue of 80 patients received radiotherapy alone. Relation of P53 and PCNA expression with clinical stage, VCA/IgA, EA/IgA, extinction of nasopharygeal tumor and neck lymph node when radiation dose was 36 Gy, and 5-year survival rate was analyzed by Chi-square test.
  
  
  RESULTS
  Positive rate of P53 in NPC tissues was 92.5%, and that of PCNA was 100%. Expression intensity of PCNA significantly related with extinction of nasopharygeal tumor, and neck lymph node when radiation dose was 36 Gy, but P53 had no significant relation with it. Expression intensities of P53 and PCNA had no significant relation with NPC clinical stage, VCA/IgA, EA/IgA, and 5-year survival rate.
  
  
  CONCLUSIONS
  P53 and PCNA relate with NPC occurrence. PCNA relates with NPC radiation sensibility, but P53 doesn't. P53 and PCNA have no relation with NPC clinical stage, VCA/IgA, EA/IgA, and prognosis.
authors.affiliation: Department of Nasopharyngeal Carcinoma,cancer Center, Sun Yat-sen University,Guangzhou, Guangdong,510060, P.R.China.
authors.forename: Hao-Yuan
authors.initials: HY
authors.lastname: Mo
authors.forename: Chang-Qing
authors.initials: CQ
authors.lastname: Zhang
authors.forename: Kai-Tao
authors.initials: KT
authors.lastname: Feng
authors.forename: Feng
authors.initials: F
authors.lastname: Zhang
authors.forename: Ming-Huang
authors.initials: MH
authors.lastname: Hong
authors.forename: Zhe-Yu
authors.initials: ZY
authors.lastname: Sun
mesh_terms: D000328:Adult; D000368:Aged; D000956:Antigens, Viral / Q000378:metabolism; D036022:Capsid Proteins / Q000378:metabolism; D002294:Carcinoma, Squamous Cell / Q000378:metabolism / Q000473:pathology / Q000532:radiotherapy / Q000821:virology; D005260:Female; D005500:Follow-Up Studies; D004854:Herpesvirus 4, Human / Q000276:immunology*; D006801:Humans; D007070:Immunoglobulin A / Q000378:metabolism; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009303:Nasopharyngeal Neoplasms / Q000378:metabolism / Q000473:pathology / Q000532:radiotherapy / Q000821:virology; D009367:Neoplasm Staging; D011379:Prognosis; D018809:Proliferating Cell Nuclear Antigen / Q000378:metabolism*; D011836:Radiation Tolerance; D012074:Remission Induction; D015996:Survival Rate; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*
chemical_list: D000956:Antigens, Viral; D036022:Capsid Proteins; C041788:Epstein-Barr viral capsid antigen; C033305:Epstein-Barr virus early antigen; D007070:Immunoglobulin A; D018809:Proliferating Cell Nuclear Antigen; D016159:Tumor Suppressor Protein p53